Crystal structure of human junctional adhesion molecule 1: Implications for reovirus binding
AUTOR(ES)
Prota, Andrea E.
FONTE
National Academy of Sciences
RESUMO
Reovirus attachment to cells is mediated by the binding of viral attachment protein σ1 to junctional adhesion molecule 1 (JAM1). The crystal structure of the extracellular region of human JAM1 (hJAM1) reveals two concatenated Ig-type domains with a pronounced bend at the domain interface. Two hJAM1 molecules form a dimer that is stabilized by extensive ionic and hydrophobic contacts between the N-terminal domains. This dimeric arrangement is similar to that observed previously in the murine homolog of JAM1, indicating physiologic relevance. However, differences in the dimeric structures of hJAM1 and murine JAM1 suggest that the interface is dynamic, perhaps as a result of its ionic nature. We demonstrate that hJAM1, but not the related proteins hJAM2 and hJAM3, serves as a reovirus receptor, which provides insight into sites in hJAM1 that likely interact with σ1. In addition, we present evidence that the previously reported structural homology between σ1 and the adenovirus attachment protein, fiber, also extends to their respective receptors, which form similar dimeric structures. Because both receptors are located at regions of cell–cell contact, this similarity suggests that reovirus and adenovirus use conserved mechanisms of entry and pathways of infection.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=404559Documentos Relacionados
- Fibrinogen Binding to Intercellular Adhesion Molecule 1: Implications for Plasmodium falciparum Adhesion
- A chimeric adenovirus vector encoding reovirus attachment protein σ1 targets cells expressing junctional adhesion molecule 1
- X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a novel dimerization motif
- A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1
- Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design